Siponimod vs placebo
Annualised relapse rate · people with multiple sclerosis
Siponimod may leads to lower annualised relapse rate compared with placebo (low certainty).
1 finding from 1 review
- RR 0.43 [0.34, 0.56]2 studies · 1739 participantsLow
Siponimod may leads to lower annualised relapse rate compared with placebo (low certainty).